Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
The new combination therapy offers a dual mechanism of action for superior intraocular pressure control
Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
Brimonidine Tartrate Ophthalmic Solution, 0.1% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure
The product is bioequivalent and therapeutically equivalent to the reference listed drug
Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
Subscribe To Our Newsletter & Stay Updated
